Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

InterMune Oritavancin Marketing Will Quadruple Firm's Sales Force To 200

  • News

Executive Summary

InterMune will add 150 sales representatives to its 48-person U.S. force over the next three years for launch of Lilly's glycopeptide antibiotic oritavancin.

You may also be interested in...



InterMune Oritavancin NDA Delayed Six Months; FDA Requests Safety Study

InterMune is in discussions with FDA regarding the design of an additional oritavancin safety study to be completed before submission of an NDA for the glycopeptide antibiotic

InterMune Oritavancin NDA Delayed Six Months; FDA Requests Safety Study

InterMune is in discussions with FDA regarding the design of an additional oritavancin safety study to be completed before submission of an NDA for the glycopeptide antibiotic

Lilly Post-Prozac Steps Include Charge Related To Ceclor Manufacturing

Lilly's post-Prozac profit warning includes a charge to eliminate excess manufacturing capacity carried over from the company's last major patent expiration, for the antibiotic Ceclor.

Table

View full table

Related Content

Pink Sheet
Tags:
Latest Headlines

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

Partisan Politics Returns To US FDA Congressional Oversight

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

See All
UsernamePublicRestriction

Register

PS038590

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By